The Phase 3 SYNCHRONIZE-START entry was last updated on 2 October 2026 and has not opened to enrolment.
Bethesda, Maryland, 2 October 2026 — The ClinicalTrials.gov registry record with identifier NCT07855900, a Phase 3 interventional study sponsored by Boehringer Ingelheim, was last updated on 2 October 2026 and carries the overall status not yet recruiting.
The registry returned 29 records in total for the search term survodutide on the day this wire was pulled.
Source documents
-
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
- Identifier
- Registry identifier NCT07855900
- Registry status
- NOT_YET_RECRUITING
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Last update posted
- 2026-10-02